Bristol Myers Squibb (CELG-RI) Total Current Liabilities (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has 18 years of Total Current Liabilities data on file, last reported at $19.2 billion in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $19.2 billion, down 20.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.2 billion (down 20.41% YoY), and the FY2025 annual result was $23.4 billion, down 1.5% from the prior year.
• Total Current Liabilities eased to $19.2 billion in Q1 2026 per CELG-RI's latest filing, from $23.4 billion in the prior quarter.
• Over five years, Total Current Liabilities peaked at $28.1 billion in Q3 2025 and troughed at $18.9 billion in Q3 2022.
• A 5-year average of $22.8 billion and a median of $22.8 billion in 2022 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2024 and 2026: Total Current Liabilities soared 35.3% in 2024, then fell 20.41% in 2026.
• A 5-year view of Total Current Liabilities shows it stood at $21.9 billion in 2022, then climbed by 1.7% to $22.3 billion in 2023, then gained by 6.79% to $23.8 billion in 2024, then retreated by 1.5% to $23.4 billion in 2025, then retreated by 18.19% to $19.2 billion in 2026.
• Business Quant data shows CELG-RI's Total Current Liabilities at $19.2 billion in Q1 2026, $23.4 billion in Q4 2025, and $28.1 billion in Q3 2025.